David E. Cohen - 05 Nov 2025 Form 3 Insider Report for Evommune, Inc.

Role: Director
Signature: /s/ Gregory S. Moss, Attorney-in-Fact
Issuer symbol: EVMN on NYSE
Transactions as of: 05 Nov 2025
Net transactions value: $0
Form type: 3
Filing time: 05 Nov 2025, 20:02:55 UTC
Previous filing: 18 Apr 2023
Next filing: 12 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cohen David E	Director	C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO	/s/ Gregory S. Moss, Attorney-in-Fact	05 Nov 2025	0001347383

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	EVMN	Common Stock						17,609	05 Nov 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	EVMN	Series Seed Preferred Stock							05 Nov 2025	Common Stock	6,056		Direct	F1
holding	EVMN	Stock Option (Right to Buy)							05 Nov 2025	Common Stock	61,356	$3.07	Direct	F2
holding	EVMN	Stock Option (Right to Buy)							05 Nov 2025	Common Stock	5,869	$3.84	Direct	F3
holding	EVMN	Stock Option (Right to Buy)							05 Nov 2025	Common Stock	5,869	$1.71	Direct	F4
holding	EVMN	Stock Option (Right to Buy)							05 Nov 2025	Common Stock	11,739	$2.99	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Series Seed Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's initial public offering, all shares of Series Seed Preferred Stock will be converted into shares of Common Stock of the Issuer.
F2	One fourth (1/4) of the shares subject to the option award vested on May 11, 2023 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F3	One fourth (1/4) of the shares subject to the option award vested on May 12, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F4	One fourth (1/4) of the shares subject to the option award vested on January 6, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F5	One fourth (1/4) of the shares subject to the option award shall vest on December 17, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.